Option chain shows key data for Arkema's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Arkema.

Arkema (OTC:ARKAY) Stock, Option Chain

ARKEMA SP ADR

Arkema is a French chemical company formerly known for its large presence in the global acrylics market. However, the company has now developed a strong portfolio of speciality materials. Arkema is organized into four segments. Adhesive solutions, advanced materials, and coatings solutions contain the more specialized material businesses. The intermediates segment houses the remaining commodity chemical businesses. Geographically, sales are split fairly equally among Europe, the US, and Asia.

chemicals shutter

Equities

Legal

Markets

ARKAY

ASGLY

BASFY

BAYRY

CTVA

DKILY

SLVYY

Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood.

PFAS&#39;s Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out

Earnings

News

Arkema Posts Drop In 2013 Profit

Arkema Posts Decline In Q1 Profit

Arkema SA

Big chemical companies had a major win on Monday, as a court of appeals reversed a decision by a lower court that would have allowed 11.8 million Ohio residents to sue for the presence of "forever chemicals"<a href="https://www.benzinga.com/markets/commodities/23/11/35958038/this-junior-miner-recently-secured-massive-investment-from-a-big-3-automaker-a-closer-look-at"> in their blood.</a>
The lawsuit targeted 3M Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), DuPont de Nemours Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>), Corteva Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>), Chemours Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>), and others, aiming to hold these companies accountable for the presence of per- and polyfluorinated substances, commonly known as PFAS, in the human body.
<h3 class="wp-block-heading">What Are ‘Forever Chemicals'?</h3>
PFAS were first developed in the mid-20th century and were quickly introduced to the market for their outstanding water-repellent and non-stick properties. DuPont was the first company to introduce the widespread use of PFAS in the development of Teflon.
PFAS can be found today in thousands of consumer products, including coated cardboard and paper wrappers for food products, water-repellent clothes, non-stick cookware as well as personal hygiene products, <a href="https://www.ewg.org/what-are-pfas-chemicals">according</a> to the Environmental Working Group, a non-profit focused on toxic chemicals, drinking water pollutants and corporate accountability.
PFAS can be found in the blood of most Americans, including newborn babies, as well as in the water supplies of many jurisdictions, affecting at least 19 million people in 43 states. They accumulate in the body and don't break down in the environment, which is why they're referred to as "forever chemicals."
While initially believed to be inert, PFAS have been associated with the onset of cancer, reproductive disease, reduced immunological response and more illnesses.
Several efforts have been made at the federal and state levels to limit the amount of PFAS and related chemicals that can legally be found in drinking water, yet the Environmental Protection Agency has not set legal boundaries, and no regulation can be found across the country except for a handful of states.
Also Read: <a href="https://www.benzinga.com/markets/equities/23/11/35984290/amazons-aws-pushes-ai-boundaries-with-new-chips-and-nvidia-partnership">Amazon&#8217;s AWS Pushes AI Boundaries With New Chips And Nvidia Partnership</a>
<h3 class="wp-block-heading">The Ohio Case</h3>
On Monday, the 6th U.S. Circuit Court of Appeals from Cincinnati rejected a previous decision by a lower Ohio court, filed by plaintiff Kevin Hardwick, which attempted to make 10 companies in the chemical industry liable to lawsuits by Ohio residents on account of PFAS present in the blood, Reuters reported.
In 2020, a study commissioned by the EPA found that more than 50 water systems in Ohio contained PFAS. A separate study from 2021 by the <a href="http://epa.ohio.gov/News/Online-News-Room/News-Releases/ohio-epa-completes-testing-drinking-water-under-ohio-pfas-action-plan">Ohio Environmental Protection Agency</a> found the chemicals in more than 100 public water systems.
The plaintiff&#8217;s case was based on the fact that five chemicals in the PFAS category were found in his blood. Hardwick is a former firefighter, and PFAS are a main ingredient in Firefighting foam.
According to Circuit Judge Raymond M. Kethledge, "Hardwick does not know what companies manufactured the particular chemicals in his bloodstream; nor does he know, or indeed have much idea whether those chemicals might someday make him sick."
Additionally, a challenge to Hardwick&#8217;s case was the fact that, among the thousands of companies that manufacture PFAS, he specifically targeted only 10 companies for the lawsuit.
3M and Chemours are, nonetheless, among the top 12 producers of PFAS globally, along with AGC (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ASGLY#OTC">ASGLY</a>), Arkema SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ARKAY#OTC">ARKAY</a>), Daikin Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DKILY#OTC">DKILY</a>), Solvay S A (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SLVYY#OTC">SLVYY</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Bayer AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAYRY#OTC">BAYRY</a>), BASF SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BASFY#OTC">BASFY</a>), Honeywell International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>), as per ChemSec data.
"Seldom is so ambitious a case filed on so slight a basis," wrote the judge, noting that Hardwick's class action attempted to represent "every person residing in the State of Ohio—some 11.8 million people."
Hardwick's inability to prove that the compounds caused any damage to his health, as well as his inability to trace those chemicals back to the companies he accused, were enough for the court to vacate the case.
Now Read:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35984611/feds-income-shortfall-puts-pressure-on-treasury-as-interest-expenses-soar-to-1-tril"> Fed&#8217;s Income Shortfall Puts Pressure On Treasury As Interest Expenses Soar To $1 Trillion</a>
Photo: Shutterstock.

PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>Loop Capital upgraded the previous rating for Albemarle Corp (NYSE:<a class="ticker" href="/stock/ALB#NYSE">ALB</a>) from Hold to Buy. In the fourth quarter, Albemarle showed an EPS of $1.17, compared to $1.73 from the year-ago quarter. At the moment, the stock has a 52-week-high of $188.35 and a 52-week-low of $48.89. Albemarle closed at $157.34 at the end of the last trading period.</li>
<li>According to Barclays, the prior rating for ManpowerGroup Inc (NYSE:<a class="ticker" href="/stock/MAN#NYSE">MAN</a>) was changed from Underweight to Overweight. ManpowerGroup earned $1.48 in the fourth quarter, compared to $2.33 in the year-ago quarter. At the moment, the stock has a 52-week-high of $99.36 and a 52-week-low of $49.57. ManpowerGroup closed at $94.41 at the end of the last trading period.</li>
<li>For Life Storage Inc (NYSE:<a class="ticker" href="/stock/LSI#NYSE">LSI</a>), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Life Storage earned $1.07 in the fourth quarter, compared to $0.96 in the year-ago quarter. The stock has a 52-week-high of $125.76 and a 52-week-low of $67.31. At the end of the last trading period, Life Storage closed at $83.93.</li>
<li>Compass Point upgraded the previous rating for RLJ Lodging Trust (NYSE:<a class="ticker" href="/stock/RLJ#NYSE">RLJ</a>) from Neutral to Buy. In the fourth quarter, RLJ Lodging showed an EPS of $0.57, compared to $0.41 from the year-ago quarter. At the moment, the stock has a 52-week-high of $16.17 and a 52-week-low of $3.88. RLJ Lodging closed at $15.74 at the end of the last trading period.</li>
<li>According to Compass Point, the prior rating for Park Hotels &amp; Resorts Inc (NYSE:<a class="ticker" href="/stock/PK#NYSE">PK</a>) was changed from Neutral to Buy. In the fourth quarter, Park Hotels &amp; Resorts showed an EPS of $0.53, compared to $0.72 from the year-ago quarter. The stock has a 52-week-high of $23.11 and a 52-week-low of $3.99. At the end of the last trading period, Park Hotels &amp; Resorts closed at $21.75.</li>
<li>For SailPoint Technologies Holdings Inc (NYSE:<a class="ticker" href="/stock/SAIL#NYSE">SAIL</a>), Needham upgraded the previous rating of Hold to Buy. SailPoint Technologies earned $0.10 in the fourth quarter, compared to $0.15 in the year-ago quarter. At the moment, the stock has a 52-week-high of $64.19 and a 52-week-low of $11.61. SailPoint Technologies closed at $56.40 at the end of the last trading period.</li>
<li>Morgan Stanley upgraded the previous rating for Spirit AeroSystems Holdings Inc (NYSE:<a class="ticker" href="/stock/SPR#NYSE">SPR</a>) from Equal-Weight to Overweight. For the fourth quarter, Spirit AeroSystems Hldgs had an EPS of $1.31, compared to year-ago quarter EPS of $0.79. The current stock performance of Spirit AeroSystems Hldgs shows a 52-week-high of $61.27 and a 52-week-low of $13.69. Moreover, at the end of the last trading period, the closing price was at $42.87.</li>
<li>For Yandex NV (NASDAQ:<a class="ticker" href="/stock/YNDX#NASDAQ">YNDX</a>), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. For the fourth quarter, Yandex had an EPS of $0.23, compared to year-ago quarter EPS of $0.26. The stock has a 52-week-high of $74.32 and a 52-week-low of $27.93. At the end of the last trading period, Yandex closed at $63.98.</li>
<li>Wells Fargo upgraded the previous rating for Bain Capital Specialty Finance Inc (NYSE:<a class="ticker" href="/stock/BCSF#NYSE">BCSF</a>) from Underweight to Equal-Weight. Bain Capital Specialty earned $0.34 in the fourth quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $19.76 and a 52-week-low of $7.11. Bain Capital Specialty closed at $14.05 at the end of the last trading period.</li>
<li>According to JP Morgan, the prior rating for Plug Power Inc (NASDAQ:<a class="ticker" href="/stock/PLUG#NASDAQ">PLUG</a>) was changed from Neutral to Overweight. Plug Power earned $0.05 in the fourth quarter, compared to $0.06 in the year-ago quarter. The current stock performance of Plug Power shows a 52-week-high of $75.49 and a 52-week-low of $2.53. Moreover, at the end of the last trading period, the closing price was at $48.38.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>According to Barclays, the prior rating for Kodiak Sciences Inc (NASDAQ:<a class="ticker" href="/stock/KOD#NASDAQ">KOD</a>) was changed from Equal-Weight to Underweight. In the fourth quarter, Kodiak Sciences showed an EPS of $0.97, compared to $0.40 from the year-ago quarter. The stock has a 52-week-high of $171.21 and a 52-week-low of $35.49. At the end of the last trading period, Kodiak Sciences closed at $129.01.</li>
<li>Barclays downgraded the previous rating for Editas Medicine Inc (NASDAQ:<a class="ticker" href="/stock/EDIT#NASDAQ">EDIT</a>) from Overweight to Equal-Weight. In the fourth quarter, Editas Medicine showed an EPS of $1.00, compared to $0.74 from the year-ago quarter. At the moment, the stock has a 52-week-high of $99.95 and a 52-week-low of $14.01. Editas Medicine closed at $43.86 at the end of the last trading period.</li>
<li>Barclays downgraded the previous rating for Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/BEAM#NASDAQ">BEAM</a>) from Overweight to Equal-Weight. For the third quarter, Beam Therapeutics had an EPS of $0.69, compared to year-ago quarter EPS of $3.31. The stock has a 52-week-high of $126.90 and a 52-week-low of $13.00. At the end of the last trading period, Beam Therapeutics closed at $89.13.</li>
<li>Deutsche Bank downgraded the previous rating for ams AG (OTC:<a class="ticker" href="/stock/AMSSY#OTC">AMSSY</a>) from Buy to Hold. At the moment, the stock has a 52-week-high of $14.00 and a 52-week-low of $4.50. ams closed at $11.65 at the end of the last trading period.</li>
<li>According to Bernstein, the prior rating for Pioneer Natural Resources Co (NYSE:<a class="ticker" href="/stock/PXD#NYSE">PXD</a>) was changed from Outperform to Market Perform. In the fourth quarter, Pioneer Natural Resources showed an EPS of $1.07, compared to $2.36 from the year-ago quarter. The stock has a 52-week-high of $153.21 and a 52-week-low of $48.62. At the end of the last trading period, Pioneer Natural Resources closed at $148.57.</li>
<li>According to HC Wainwright &amp; Co., the prior rating for ZIOPHARM Oncology Inc (NASDAQ:<a class="ticker" href="/stock/ZIOP#NASDAQ">ZIOP</a>) was changed from Buy to Neutral. For the fourth quarter, ZIOPHARM Oncology had an EPS of $0.11, compared to year-ago quarter EPS of $0.09. The current stock performance of ZIOPHARM Oncology shows a 52-week-high of $5.95 and a 52-week-low of $1.79. Moreover, at the end of the last trading period, the closing price was at $5.33.</li>
<li>According to Bernstein, the prior rating for Apache Corp (NASDAQ:<a class="ticker" href="/stock/APA#NASDAQ">APA</a>) was changed from Outperform to Market Perform. For the fourth quarter, Apache had an EPS of $0.05, compared to year-ago quarter EPS of $0.08. At the moment, the stock has a 52-week-high of $26.96 and a 52-week-low of $3.80. Apache closed at $19.73 at the end of the last trading period.</li>
<li>For WSFS Financial Corp (NASDAQ:<a class="ticker" href="/stock/WSFS#NASDAQ">WSFS</a>), Piper Sandler downgraded the previous rating of Overweight to Neutral. In the fourth quarter, WSFS Financial showed an EPS of $1.16, compared to $0.96 from the year-ago quarter. The current stock performance of WSFS Financial shows a 52-week-high of $55.08 and a 52-week-low of $17.84. Moreover, at the end of the last trading period, the closing price was at $53.14.</li>
<li>Wells Fargo downgraded the previous rating for TC Pipelines LP (NYSE:<a class="ticker" href="/stock/TCP#NYSE">TCP</a>) from Overweight to Equal-Weight. TC Pipelines earned $1.01 in the fourth quarter, compared to $0.95 in the year-ago quarter. The stock has a 52-week-high of $41.20 and a 52-week-low of $18.00. At the end of the last trading period, TC Pipelines closed at $29.26.</li>
<li>According to Morgan Stanley, the prior rating for TechnipFMC PLC (NYSE:<a class="ticker" href="/stock/FTI#NYSE">FTI</a>) was changed from Overweight to Equal-Weight. TechnipFMC earned $0.05 in the fourth quarter, compared to $0.03 in the year-ago quarter. The current stock performance of TechnipFMC shows a 52-week-high of $16.17 and a 52-week-low of $4.49. Moreover, at the end of the last trading period, the closing price was at $8.21.</li>
<li>According to RBC Capital, the prior rating for Pactiv Evergreen Inc (NASDAQ:<a class="ticker" href="/stock/PTVE#NASDAQ">PTVE</a>) was changed from Outperform to Sector Perform. Pactiv Evergreen earned $0.10 in the fourth quarter. At the moment, the stock has a 52-week-high of $19.61 and a 52-week-low of $10.40. Pactiv Evergreen closed at $13.98 at the end of the last trading period.</li>
<li>JP Morgan downgraded the previous rating for Agios Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="/stock/AGIO#NASDAQ">AGIO</a>) from Overweight to Neutral. Agios Pharmaceuticals earned $1.41 in the fourth quarter, compared to $1.60 in the year-ago quarter. The current stock performance of Agios Pharmaceuticals shows a 52-week-high of $58.93 and a 52-week-low of $27.77. Moreover, at the end of the last trading period, the closing price was at $47.44.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>With an Overweight rating, Morgan Stanley initiated coverage on Sana Biotechnology Inc (NASDAQ:<a class="ticker" href="/stock/SANA#NASDAQ">SANA</a>). The price target seems to have been set at $40.00 for Sana Biotechnology. The current stock performance of Sana Biotechnology shows a 52-week-high of $44.60 and a 52-week-low of $29.99. Moreover, at the end of the last trading period, the closing price was at $30.74.</li>
<li>Morgan Stanley initiated coverage on Boston Beer Co Inc (NYSE:<a class="ticker" href="/stock/SAM#NYSE">SAM</a>) with an Overweight rating. The price target for Boston Beer Co is set to $1400.00. For the fourth quarter, Boston Beer Co had an EPS of $2.64, compared to year-ago quarter EPS of $1.24. The current stock performance of Boston Beer Co shows a 52-week-high of $1236.57 and a 52-week-low of $290.02. Moreover, at the end of the last trading period, the closing price was at $1029.82.</li>
<li>Morgan Stanley initiated coverage on TELUS International (Cda) Inc (NYSE:<a class="ticker" href="/stock/TIXT#NYSE">TIXT</a>) with a Equal-Weight rating. The price target for TELUS International is set to $31.00. In the fourth quarter, TELUS International showed an EPS of $0.09, compared to $0.14 from the year-ago quarter. The stock has a 52-week-high of $33.60 and a 52-week-low of $28.00. At the end of the last trading period, TELUS International closed at $29.12.</li>
<li>With a Buy rating, Stifel initiated coverage on Codexis Inc (NASDAQ:<a class="ticker" href="/stock/CDXS#NASDAQ">CDXS</a>). The price target seems to have been set at $30.00 for Codexis. Codexis earned $0.06 in the fourth quarter, compared to $0.01 in the year-ago quarter. The current stock performance of Codexis shows a 52-week-high of $29.56 and a 52-week-low of $8.43. Moreover, at the end of the last trading period, the closing price was at $22.11.</li>
<li>Credit Suisse initiated coverage on TELUS International (Cda) Inc (NYSE:<a class="ticker" href="/stock/TIXT#NYSE">TIXT</a>) with a Neutral rating. The price target for TELUS International is set to $33.00. TELUS International earned $0.09 in the fourth quarter, compared to $0.14 in the year-ago quarter. The stock has a 52-week-high of $33.60 and a 52-week-low of $28.00. At the end of the last trading period, TELUS International closed at $29.12.</li>
<li>Berenberg initiated coverage on Repare Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/RPTX#NASDAQ">RPTX</a>) with a Buy rating. The price target for Repare Therapeutics is set to $51.00. In the third quarter, Repare Therapeutics showed an EPS of $0.37, compared to $5.03 from the year-ago quarter. At the moment, the stock has a 52-week-high of $46.44 and a 52-week-low of $21.45. Repare Therapeutics closed at $32.90 at the end of the last trading period.</li>
<li>RBC Capital initiated coverage on Atotech Ltd (NYSE:<a class="ticker" href="/stock/ATC#NYSE">ATC</a>) with an Outperform rating. The price target for Atotech is set to $23.00. At the moment, the stock has a 52-week-high of $20.83 and a 52-week-low of $17.00. Atotech closed at $20.18 at the end of the last trading period.</li>
<li>With a Neutral rating, Credit Suisse initiated coverage on TELUS Corp (NYSE:<a class="ticker" href="/stock/TU#NYSE">TU</a>). The price target seems to have been set at $33.00 for TELUS. For the fourth quarter, TELUS had an EPS of $0.17, compared to year-ago quarter EPS of $0.52. The current stock performance of TELUS shows a 52-week-high of $38.66 and a 52-week-low of $13.54. Moreover, at the end of the last trading period, the closing price was at $20.04.</li>
<li>With an Outperform rating, Credit Suisse initiated coverage on Atotech Ltd (NYSE:<a class="ticker" href="/stock/ATC#NYSE">ATC</a>). The price target seems to have been set at $23.00 for Atotech. At the moment, the stock has a 52-week-high of $20.83 and a 52-week-low of $17.00. Atotech closed at $20.18 at the end of the last trading period.</li>
<li>Credit Suisse initiated coverage on Opendoor Technologies Inc (NASDAQ:<a class="ticker" href="/stock/OPEN#NASDAQ">OPEN</a>) with an Outperform rating. The price target for Opendoor Technologies is set to $37.00. At the moment, the stock has a 52-week-high of $39.24 and a 52-week-low of $21.41. Opendoor Technologies closed at $28.02 at the end of the last trading period.</li>
<li>SVB Leerink initiated coverage on Landos Biopharma Inc (NASDAQ:<a class="ticker" href="/stock/LABP#NASDAQ">LABP</a>) with an Outperform rating. The price target for Landos Biopharma is set to $20.00. At the moment, the stock has a 52-week-high of $15.35 and a 52-week-low of $10.77. Landos Biopharma closed at $13.48 at the end of the last trading period.</li>
<li>With a Buy rating, HC Wainwright &amp; Co. initiated coverage on F-star Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/FSTX#NASDAQ">FSTX</a>). The price target seems to have been set at $35.00 for F-star Therapeutics. The current stock performance of F-star Therapeutics shows a 52-week-high of $12.20 and a 52-week-low of $6.61. Moreover, at the end of the last trading period, the closing price was at $8.27.</li>
<li>With a Buy rating, HC Wainwright &amp; Co. initiated coverage on Angion Biomedica Corp (NASDAQ:<a class="ticker" href="/stock/ANGN#NASDAQ">ANGN</a>). The price target seems to have been set at $100.00 for Angion Biomedica. The stock has a 52-week-high of $26.30 and a 52-week-low of $16.00. At the end of the last trading period, Angion Biomedica closed at $17.34.</li>
<li>Needham initiated coverage on DZS Inc (NASDAQ:<a class="ticker" href="/stock/DZSI#NASDAQ">DZSI</a>) with a Buy rating. The price target for DZS is set to $23.00. The current stock performance of DZS shows a 52-week-high of $18.90 and a 52-week-low of $2.90. Moreover, at the end of the last trading period, the closing price was at $16.64.</li>
<li>With a Neutral rating, Goldman Sachs initiated coverage on Sana Biotechnology Inc (NASDAQ:<a class="ticker" href="/stock/SANA#NASDAQ">SANA</a>). The price target seems to have been set at $40.00 for Sana Biotechnology. The current stock performance of Sana Biotechnology shows a 52-week-high of $44.60 and a 52-week-low of $29.99. Moreover, at the end of the last trading period, the closing price was at $30.74.</li>
<li>With a Buy rating, Jefferies initiated coverage on Five9 Inc (NASDAQ:<a class="ticker" href="/stock/FIVN#NASDAQ">FIVN</a>). The price target seems to have been set at $220.00 for Five9. In the fourth quarter, Five9 showed an EPS of $0.34, compared to $0.27 from the year-ago quarter. The current stock performance of Five9 shows a 52-week-high of $194.03 and a 52-week-low of $52.51. Moreover, at the end of the last trading period, the closing price was at $185.24.</li>
<li>Piper Sandler initiated coverage on Sensei Biotherapeutics Inc (NASDAQ:<a class="ticker" href="/stock/SNSE#NASDAQ">SNSE</a>) with an Overweight rating. The price target for Sensei Biotherapeutics is set to $25.00. At the moment, the stock has a 52-week-high of $26.50 and a 52-week-low of $15.45. Sensei Biotherapeutics closed at $16.50 at the end of the last trading period.</li>
<li>Goldman Sachs initiated coverage on ON24 Inc (NYSE:<a class="ticker" href="/stock/ONTF#NYSE">ONTF</a>) with a Buy rating. The price target for ON24 is set to $88.00. The stock has a 52-week-high of $81.98 and a 52-week-low of $46.37. At the end of the last trading period, ON24 closed at $56.31.</li>
<li>With a Buy rating, Needham initiated coverage on ON24 Inc (NYSE:<a class="ticker" href="/stock/ONTF#NYSE">ONTF</a>). The price target seems to have been set at $70.00 for ON24. At the moment, the stock has a 52-week-high of $81.98 and a 52-week-low of $46.37. ON24 closed at $56.31 at the end of the last trading period.</li>
<li>KeyBanc initiated coverage on ON24 Inc (NYSE:<a class="ticker" href="/stock/ONTF#NYSE">ONTF</a>) with an Overweight rating. The price target for ON24 is set to $70.00. The stock has a 52-week-high of $81.98 and a 52-week-low of $46.37. At the end of the last trading period, ON24 closed at $56.31.</li>
<li>With an Overweight rating, Piper Sandler initiated coverage on ON24 Inc (NYSE:<a class="ticker" href="/stock/ONTF#NYSE">ONTF</a>). The price target seems to have been set at $70.00 for ON24. At the moment, the stock has a 52-week-high of $81.98 and a 52-week-low of $46.37. ON24 closed at $56.31 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Intraday Update

Analyst Ratings

AGIO

AMSSY

ANGN

BCSF

BEAM

CBWBF

CDXS

DZSI

EDIT

FIVN

FSTX

GNHAF

LABP

ONTF

OPEN

PEGRY

PLUG

PPRUY

PTVE

RPTX

SAIL

SANA

SBSNF

SNSE

THNPF

TIXT

TKAYY

VOPKY

WSFS

WTKWY

YNDX

ZIOP

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021

Kepler Cheuvreux analyst Martin Roediger upgrades Arkema (OTC:<a class="ticker" href="/stock/ARKAY#OTC">ARKAY</a>) from Hold to Buy.

Kepler Cheuvreux Upgrades Arkema to Buy

Movers

Trading Ideas

AACAF

AACAY

AAGIY

AAIGF

AAMMF

AAUKF

AAVMY

AAVVF

ABBRF

ABCP

ABILF

ABMC

ABNAF

ABSSF

ACDVF

ACGBY

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

ACHFF

ACKRF

ACNDF

ACNNF

ACOPF

ACRL

ACSAY

ACUIF

ADAD

ADDDF

ADDYY

ADMT

ADYEY

AEGOF

AERG

AETUF

AEXAY

AFLYY

AGCBF

AGESY

AGFAF

AGGFF

AHCHY

AHEXY

ALTERNATE HEALTH CORP ORD by Alternate Health Corp.

AHGIF

AHKSF

AHKSY

AHWSF

AIBGY

AIBRF

AIQUY

AIRRF

AISSF

AJMPF

AJXGF

AKAOQ

AKBTY

AKZOY

ALBY

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALFVY

ALIAF

ALIF

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLVF

ALMTF

ALPMY

ALSMY

ALVOF

ALYI

AMADY

AMAZ

AMBBY

AMIGY

AMKAF

AMKBF

AMKBY

AMLZF

AMMX

AMRQQ

AMXEF

ANEWF

ANGPY

ANPDF

ANPDY

ANSLY

ANTH

ANACONDA MINING INC by Anaconda Mining Inc.

ANXGF

Australia and New Zealand Banking Group Limited

ANZBY

ANZLY

AOIFF

AOMFF

ASCOT RESOURCES LTD by Ascot Resources Ltd.

AOTVF

APELY

APHD

APMCF

AQARF

ARAFF

ARESF

ARGKF

ARNGF

ARREF

ARRRF

Stocks That Hit 52-Week Highs On Tuesday

Goldman Sachs downgrades Arkema (OTC:<a class="ticker" href="/stock/ARKAY#OTC">ARKAY</a>) from Neutral to Sell.

Goldman Sachs Downgrades Arkema to Sell

Arkema SA (OTC: <a class="ticker" href="/stock/arkay#OTC">ARKAY</a>) reported a drop in its 2013 net profit. 

Arkema's net profit for the year declined 24% to 168 million euros ($232 million), while sales slipped 4.6% to EUR6.1 billion. 

Its earnings before interest, taxes, depreciation and amortization declined 9.4% to EUR902 million. Arkema projects sales to increase to EUR8 billion by 2016.

Arkema shares closed at $106.15 yesterday.

Arkema SA (OTC: <a class="ticker" href="/stock/arkay#OTC">ARKAY</a>) reported a decline in its net profit fell for the first quarter.

Arkema's quarterly sales gained 14% to EUR1.62 billion. Its earnings before interest, taxes, depreciation and amortization fell to EUR253 million, from EUR289 million.

Arkema SA (OTC: ARKAY) announced its plans to acquire Hipro Polymers and Casda Biomaterials for a total $365 million.

Arkema shares fell 0.63% to close at $57.00 on Friday.

Arkema To Acquire Two Chinese Chemical Companies

Warning: ARKAY is at high risk of cutting its dividend

Arkema S.A. ( ($ARKAY) ) has released its Q3 earnings. Here is a breakdown of the information Arkema S.A. presented to its investors. Arkema S.A. i...

Arkema's Strong Performance Amidst Challenging Conditions

In a report released on November 6, Martin Roediger from Kepler Capital maintained a Buy rating on Arkema (0IB0 – Research Report), with a price ta...

Kepler Capital  Keeps Their Buy Rating on Arkema (0IB0)

Arkema S.A. 2024 Q3 - Results - Earnings Call Presentation

Arkema S.A. (ARKAF) Q3 2024 Earnings Call Transcript

In a report released on November 11, Martin Roediger from Kepler Capital maintained a Buy rating on Arkema (0IB0 – Research Report), with a price t...

Arkema (0IB0) Receives a Buy from Kepler Capital

Barclays analyst Alex Stewart maintained a Buy rating on Arkema (0IB0 – Research Report) today. The company's shares closed yesterday at €75.01. Ac...

Barclays Reaffirms Their Buy Rating on Arkema (0IB0)

Citi upgraded Arkema (ARKAY) to Buy from Neutral with a price target of EUR 100, up from EUR 93.50, in a sector note on European Diversified Chemic...

Arkema upgraded to Buy from Neutral at Citi

Arkema: This French Chemical Company Is Now Cheap Enough To Go Long

ARKAF

Arkema

Comments

Arkema

Arkema (ARKAY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga